Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 4/20 | 0.47 |
| ▸ | CALCRL | Q16602 | 5/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | GRB2 | P62993 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30571124 | 0.86 | XIAP (0.48) | CAPN1CALCRLNTSR1CTSBXIAP | |
| SCHEMBL31281377 | 0.85 | CALCRL (0.51) | CAPN1CALCRLSLC6A2XIAP | |
| SCHEMBL30906513 | 0.85 | RAMP3 (0.55) | NTSR1 | |
| SCHEMBL30547998 | 0.85 | CAPN1 (0.48) | CAPN1CALCRLCTSBSLC6A2 | |
| SCHEMBL30883252 | 0.84 | CAPN1 (0.46) | CAPN1CALCRLNTSR1STAT3 | |
| SCHEMBL30390361 | 0.84 | NTSR1 (0.51) | CAPN1CALCRLNTSR1CTSBKDM1A | |
| SCHEMBL29876433 | 0.84 | CAPN1 (0.52) | CAPN1CALCRLNTSR1STAT3CTSB | |
| SCHEMBL31151650 | 0.83 | NTSR1 (0.49) | CAPN1NTSR1CTSBKDM1A | |
| SCHEMBL30286598 | 0.83 | NTSR1 (0.50) | CAPN1CALCRLNTSR1CTSBKDM1A | |
| SCHEMBL30906475 | 0.82 | RAMP3 (0.53) | CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4591934-A2 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-4523749-A2 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12214015-B2 | Use of c-type natriuretic peptide variants to treat osteoarthritis | BIOMARIN PHARMACEUTICAL INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4029512-A1 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-4019038-A2 | USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITIS | BioMarin Pharmaceutical Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220160836-A1 | USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITIS | BIOMARIN PHARMACEUTICAL INC. | 2022-05-26 | — | — | US | disclosed |